I think it’s a very, very important question and step, but the problem is that the pathologists are already much ahead of us. So they are defining a lot of new fusions, for example, or mutations, which in practice we still cannot target. So the pharmaceutical industry, of course, needs to adapt to this very quick development. And for us, we have, according to the new WHO classification, we have 187 different subtypes...
I think it’s a very, very important question and step, but the problem is that the pathologists are already much ahead of us. So they are defining a lot of new fusions, for example, or mutations, which in practice we still cannot target. So the pharmaceutical industry, of course, needs to adapt to this very quick development. And for us, we have, according to the new WHO classification, we have 187 different subtypes. So as you can imagine, in these classifications, there are also subtypes with different fusions, and we do not know the significance of many of them. So unfortunately, in sarcomas, we do not have really biomarkers that are available which we can rely on. There are some, like for example, NTRK fusions, where we of course know how to target it with the available drugs and we know which response rates are going to be expected, but unfortunately, it’s a very, very new field to first discover all the possibilities we have and then to try to cover them with the according drugs or even to find biomarkers so that we can select our patients, because this, of course, is one of the most important points, to select the right patients to receive the right therapy and not put all of them in one basket and treat them in the same way.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.